Clinical Epidemiology最新文献

{"title":"Self-Selection Bias in Randomized and Observational Studies on Screening Mammography: A Quantitative Assessment.","authors":"Philippe Autier","doi":"10.2147/CLEP.S515464","DOIUrl":"https://doi.org/10.2147/CLEP.S515464","url":null,"abstract":"<p><strong>Background: </strong>Observational studies aimed at evaluating the effectiveness of screening mammography are prone to self-selection due to differences in personal characteristics between women attending and those not attending screening. A method based on a quantity <i>Dr</i> has been promoted to correct for this bias, <i>Dr</i> being the risk of breast cancer death in a group of women not attending screening compared to the risk of breast cancer death in a population without screening.</p><p><strong>Objective: </strong>To estimate the amount of self-selection in observational studies aimed at evaluating screening mammography effectiveness and to estimate <i>Dr</i> quantities needed to correct for this bias.</p><p><strong>Methods: </strong>A first step quantified self-selection and <i>Dr</i> quantities specific to Swedish randomized trials using the most recent publications. A second step estimated self-selection specific to cohort studies on screening mammography effectiveness using the relative risk of 0.54 for all-cause death from these studies and the relative risk of all-cause death of 0.98 reported in Swedish trials. Using self-selection estimated from cohort studies, the <i>Dr</i> quantity needed to correct observational studies on screening mammography effectiveness was estimated. In a last step, corrections for self-selection in observational studies on screening mammography were retrieved.</p><p><strong>Results: </strong>The self-selection bias was 2.10 in Swedish trials. Self-selection in cohort studies was computed as (0.98/0.54) = 1.78. The <i>Dr</i> quantity required to correct results of observational studies was 1.53. In 19 case-control and cohort studies on screening mammography effectiveness, the median <i>Dr</i> quantity used for correction purposes was 1.16 (IQR: 1.11-1.28).</p><p><strong>Conclusion: </strong>Compared to women attending screening, the risk of breast cancer death was approximately two times greater in women not attending screening. This increased risk was independent of screening effects. Most observational studies have overestimated the effectiveness of screening mammography because they used <i>Dr</i> quantities that were too small to correct for self-selection.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":"17 ","pages":"441-450"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Validity and Completeness of the Septoplasty Surgical Procedure Code in the Danish National Patient Registry.","authors":"Janni Øre Bredahl, Anders Bo Rønnegaard, Kenneth Stockmann Larsen, Anette Drøhse Kjeldsen","doi":"10.2147/CLEP.S493386","DOIUrl":"https://doi.org/10.2147/CLEP.S493386","url":null,"abstract":"<p><strong>Introduction: </strong>Ensuring the validity and completeness of clinical data is crucial when utilizing nationwide registers such as the Danish National Patient Registry (DNPR) for epidemiological research. The literature on this topic is, however, strongly lacking for Ear-nose-and-throat (ENT) surgery. The aim of this study was to assess the validity and completeness of the septoplasty surgical procedure code in DNPR.</p><p><strong>Methods: </strong>This population-based validation and completeness study included all cases of septoplasty surgical procedure codes registered in the DNPR in 2021 and 2022 at the ENT department at Odense University Hospital (OUH) in Denmark. The unique personal registration number was used to identify cases from the DNPR in OUH data registrations. All surgical notes were evaluated manually to determine whether septoplasty had been performed. The primary outcomes were validity (PPV) and completeness assessed as the sensitivity, presented with 95% confidence intervals (CI).</p><p><strong>Results: </strong>A total of 479 cases were identified from the DNPR. Upon evaluation of the surgical notes and after withdrawal of duplicates, 470 cases were confirmed to have undergone septoplasty, resulting in a PPV of 99% (95% CI (97.6-99.7)). From the OUH data registrations, 485 registrations of septoplasty were identified. Evaluation of the surgical notes left 475 cases of confirmed septoplasty, corresponding to five missing cases in the DNPR, resulting in a sensitivity of 99% (95% CI (97.6-99.7)).</p><p><strong>Conclusion: </strong>This study showed high validity and completeness for registrations of the septoplasty surgical procedure code in the DNPR. We therefore conclude that the DNPR is a reliable tool for epidemiological research concerning septoplasty.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":"17 ","pages":"435-440"},"PeriodicalIF":3.4,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12047226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of SGLT2 Inhibitors on Diabetes Progression in Statin-Treated Patients: A Population-Based Cohort Study.","authors":"Jack Ssu-Chi Cheng, Fang-Ju Lin, Chih-Min Fu, Shin-Yi Lin, Chih-Yuan Wang, Hsin-Yi Huang, Chi-Chuan Wang","doi":"10.2147/CLEP.S505242","DOIUrl":"https://doi.org/10.2147/CLEP.S505242","url":null,"abstract":"<p><strong>Background: </strong>Statins, though widely used, may accelerate diabetes progression, necessitating interventions to counteract this effect.</p><p><strong>Purpose: </strong>To compare the effect of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and sulfonylureas or meglitinides on diabetes progression in individuals receiving statins.</p><p><strong>Patients and methods: </strong>This retrospective cohort study utilized data from the National Health Insurance Research Database of Taiwan. We included patients with diabetes receiving statins and newly initiated SGLT2is or sulfonylureas/meglitinides between July 1, 2016 and December 31, 2020. Diabetes progression was defined as insulin initiation, increase in antidiabetic medication class, or occurrence of new acute hyperglycemic complications. Propensity score matching was used to adjust baseline characteristics. Cox proportional hazards regression was used to calculate the hazard ratios for diabetes progression between users of SGLT2is and those of sulfonylureas or meglitinides. The statistical significance level was set at 0.05 for all analyses.</p><p><strong>Results: </strong>SGLT2i users had a significantly lower risk of diabetes progression compared to sulfonylurea/meglitinide users (HR: 0.53, 95% CI: 0.50-0.57, p-value < 0.001). Similar results were found in insulin initiation (HR: 0.48, 95% CI: 0.38-0.61, p-value < 0.001) and increase in antidiabetic medication class (HR: 0.53, 95% CI: 0.50-0.57, p-value < 0.17). However, the risk of new acute glycemic complications did not significantly differ between groups (HR: 2.47, 95% CI: 0.67-9.08, p-value = 0.17).</p><p><strong>Conclusion: </strong>SGLT2is may be an effective second-line therapy for statin-treated patients by slowing diabetes progression and potentially mitigating statin-induced metabolic disturbances. Further research, including randomized controlled trials or observational studies with comprehensive laboratory data, is needed to confirm these findings and evaluate their broader applicability.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":"17 ","pages":"421-433"},"PeriodicalIF":3.4,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12024468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo.","authors":"Signe Borgquist, Maj-Britt Jensen, Cecilie Linea Bendorff, Peer Christiansen, Birgitte Vrou Offersen, Annette Raskov Kodahl, Marianne Ewertz, Anders Bonde Jensen, Thomas P Ahern, Deirdre Cronin-Fenton, Bent Ejlertsen","doi":"10.2147/CLEP.S509873","DOIUrl":"https://doi.org/10.2147/CLEP.S509873","url":null,"abstract":"<p><strong>Purpose: </strong>Statin use has been consistently associated with improved clinical outcomes (especially recurrence) in breast cancer in multiple observational studies backed by compelling preclinical evidence. The strength of this evidence warrants a clinical trial to test the efficacy of statin exposure on breast cancer recurrence.</p><p><strong>Patients and methods: </strong>The double-blind, phase III, randomized, placebo-controlled MASTER (MAmmary cancer STatins in ER positive breast cancer) trial includes women diagnosed with early-stage, estrogen receptor-positive (ER+) breast cancer who are candidates for systemic (neo)adjuvant therapy. Enrolled patients are given standard (neo)adjuvant therapy and additionally randomized to either atorvastatin (80 mg/day) or placebo for two years. The trial's primary outcome is invasive disease-free survival (IDFS), with a target accrual of 3360 patients in total to achieve 80% power (two-sided alpha=0.05) to detect a 25% reduction in the risk of an IDFS event comparing the statin and placebo arms. At 3-, 6-, 12-, and 24-month follow-up time points, patients will have blood drawn for biomarker studies, answer patient-reported outcome (PRO) questionnaires, and control for adverse events. Subsequently, patients will receive annual PRO-criteria for Adverse Events (CTCAE) questionnaires until the completion of their 10 years of follow-up. Secondary endpoints include additional clinical endpoints; pathological response (neo-adjuvant treated patients), recurrence-free survival, distant-recurrence-free interval, overall survival and cardiac death-free interval, co-morbidity, and health-related quality-of-life measured by PRO-CTCAE questionnaires during and beyond study medication. Translational endpoints are evaluated in collected blood- and tumor samples.</p><p><strong>Discussion: </strong>If a protective effect of statins on breast cancer recurrence is supported by evidence from the MASTER trial, then the indications for a safe, well-tolerated, and inexpensive treatment can be expanded towards improved clinical outcomes for breast cancer patients.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":"17 ","pages":"409-419"},"PeriodicalIF":3.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12011050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental Disorders in Danish Hospital Registers: A Review of Content and Possibilities for Epidemiological Research.","authors":"Oleguer Plana-Ripoll, Xiaoqin Liu, Ole Köhler-Forsberg, Henrik Toft Sørensen, Natalie C Momen","doi":"10.2147/CLEP.S509147","DOIUrl":"https://doi.org/10.2147/CLEP.S509147","url":null,"abstract":"<p><strong>Background: </strong>The Danish national hospital registers are a rich source of data for psychiatric epidemiology. The potential to identify diagnosed mental disorders in the Danish population has resulted in a plethora of important research studies. However, no recent review of these research sources exists.</p><p><strong>Objective: </strong>To review the content, data quality and epidemiological considerations regarding mental disorders in the Danish hospital registers.</p><p><strong>Methods: </strong>We provide information on the setting, history, and data access regarding mental disorders in the Danish hospital registers (defined according to the International Classification of Diseases, Tenth Revision, F group Mental and behavioural disorder codes). We describe the registration of mental disorders over time in the Danish hospital registers, by providing counts of individuals diagnosed with mental disorders each year, by types of mental disorders, diagnosis, hospital contact, and contact unit. We also provide information on considerations when using these data sources, including data quality. For this, we searched PubMed to identify validation studies of coding of mental disorder diagnoses.</p><p><strong>Results: </strong>Between 1969 and 2022, 1,136,280 individuals (10.7% of all individuals who resided in Denmark in this period) have been registered as having a mental disorder as a primary or secondary diagnosis in a psychiatric unit in Denmark at least once. The type of contact and unit diagnoses were made in varied by mental disorder type. The literature indicates that a large proportion of coded diagnoses in the Danish hospital registers of mental disorders were considered valid.</p><p><strong>Conclusion: </strong>We provide an overview of the available data for investigating mental disorders in the Danish hospital registers. We raise awareness of the limitations researchers should be aware of when using this data and discuss their implications. Careful consideration should be given to these during study design and when reporting findings from register-based studies on diagnosed mental disorders.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":"17 ","pages":"387-407"},"PeriodicalIF":3.4,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of Carbon Monoxide Poisoning in Asian Countries From 1990 to 2021 and Its Projection Until 2030: An Analysis of the Global Burden of Disease Study 2021.","authors":"Jiahao Xie, Chengen Wu, Zhenpeng Zhao, Zhihua Cao, Xiaoqing Jin","doi":"10.2147/CLEP.S512786","DOIUrl":"https://doi.org/10.2147/CLEP.S512786","url":null,"abstract":"<p><strong>Background: </strong>Carbon monoxide (CO) poisoning represents a significant contributor to injury burden across Asia. This study seeks to assess the burden of CO poisoning in Asia from 1990 to 2021 utilizing data from the Global Burden of Disease Study (GBD) 2021.</p><p><strong>Methods: </strong>Data on the burden of CO poisoning across 49 Asian countries were extracted from GBD 2021. The variations in burden were analyzed according to year, gender, location, age, and Socio-Demographic Index (SDI). Analyses included Joinpoint analysis to evaluate temporal trends, the age-period-cohort model to assess disease burden trends, the slope index of inequality and concentration index for assessing health disparities, frontier analysis for estimating potential outcomes based on developmental stages, and the auto-regressive integrated moving average model to predict the disability-adjusted life year (DALY) rates.</p><p><strong>Results: </strong>During 1990-2021, the age-standardized incidence rate (average annual percent change (AAPC) = -0.83, 95% CI: -0.94 to -0.73), age-standardized mortality rate (AAPC = -2.01, 95% CI: -2.20 to -1.81), and DALY rates (AAPC = -2.39, 95% CI: -2.54 to -2.23) for CO poisoning across Asia declined. In 2021, females experienced a lower burden than males, and countries in higher latitudes bore a greater burden. The burden was more pronounced in extreme age groups, with an elevated cohort risk in the 1967-1971 birth cohort (relative risk (RR) = 1.045, 95% CI: 0.96-1.14). Health inequality analyses showed a reduction in disparities between countries with varying SDI levels. Frontier analysis identified potential improvements in reducing the burden across different countries. However, there was no notable correlation between this burden and SDI levels. The age-standardized disability-adjusted life year rate is predicted to continue declining from 2022 to 2030.</p><p><strong>Conclusion: </strong>This study analyzes the burden of CO poisoning in Asia, revealing a decline from 1990 to 2021, with variations across countries and higher burdens in males and extreme age groups. It suggests a reduction in health inequalities and forecasts a continued decline in the burden by 2030.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":"17 ","pages":"367-386"},"PeriodicalIF":3.4,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracting Cognitive Impairment Assessment Information From Unstructured Notes in Electronic Health Records Using Natural Language Processing Tools: Validation with Clinical Assessment Data.","authors":"Kuan-Yuan Wang, Mufaddal Mahesri, John Novoa-Laurentiev, Lily G Bessette, Cassandra York, Heidi Zakoul, Su Been Lee, Kerry Ngan, Li Zhou, Dae Hyun Kim, Kueiyu Joshua Lin","doi":"10.2147/CLEP.S504259","DOIUrl":"https://doi.org/10.2147/CLEP.S504259","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to develop a Natural Language Processing (NLP) algorithm to extract cognitive scores from electronic health records (EHR) data and compare them with cognitive function recorded by Centers for Medicare & Medicaid Services (CMS)-mandated clinical assessments in nursing homes and home health visits.</p><p><strong>Patients and methods: </strong>We identified a cohort of Medicare beneficiaries who had either the Minimum Data Set (MDS) or Outcome and Assessment Information Set (OASIS) linked to EHR data from the Research Patient Data Registry (Mass General Brigham, Boston, MA) from 2010 to 2019. We applied an NLP approach to identify the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE) scores from unstructured clinician notes in EHR. Using the NLP-extracted MoCA or MMSE scores from EHR, we compared mean differences of extracted MoCA or MMSE by cognition status determined by MDS (impaired vs intact cognition) and OASIS (severe impairment vs intact cognition) data, respectively.</p><p><strong>Results: </strong>Our study cohort had 7419 patients who had MDS (19.7%) or OASIS (80.3%) assessments, with a mean age of 80 (SD=7) years and 60% female. In EHR, the NLP algorithm extracted cognitive test scores with 97% accuracy (95% CI: 92-99%) for MoCA and 100% accuracy (95% CI: 84-100%) for MMSE. In MDS, the mean difference in extracted MoCA was -5.6 (95% CI: -8.7, -2.4, p=0.0008), and the mean difference in extracted MMSE was -7.9 (95% CI: -12.4, -3.5, p=0.0012). In OASIS, the mean difference in extracted MoCA and extracted MMSE was -4.8 (95% CI: -9.1, -0.6, p=0.0006) and -4.5 (95% CI: -9.5, -0.5, p=0.0182), respectively.</p><p><strong>Conclusion: </strong>We developed an NLP algorithm to accurately extract cognitive scores from unstructured EHR, and these extracted cognitive scores were well correlated with cognition function recorded in CMS-mandated clinical assessments. This could help researchers identify patients with various degrees of cognitive impairment in EHR-based research.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":"17 ","pages":"353-365"},"PeriodicalIF":3.4,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dispensing Patterns of Inhaled Asthma Medication Before and During COVID-19 Among Young Adults in the Netherlands: A Retrospective Inception Cohort Study.","authors":"Guiling Zhou, Irene Mommers, Catharina C M Schuilinga-Veninga, Jens H J Bos, Katrien Oude Rengerink, Anna Maria Gerdina Pasmooij, Peter G M Mol, Debbie van Baarle, Geertruida H de Bock, Job F M van Boven, Eelko Hak","doi":"10.2147/CLEP.S496841","DOIUrl":"https://doi.org/10.2147/CLEP.S496841","url":null,"abstract":"<p><strong>Background: </strong>The impact of the coronavirus disease 2019 (COVID-19) pandemic on asthma medication trajectories, including changes in medication type or dosage, remains unclear. This study compared dispensing patterns among adults who initiated asthma inhalers before pandemic (cohorts 2014 and 2017) and during pandemic (cohort 2020).</p><p><strong>Methods: </strong>We performed retrospective inception cohort study using University of Groningen IADB.nl community pharmacy dispensing database. Individuals aged 16-44 years who initiated inhaled asthma treatment in 2014, 2017, or 2020 were followed for 2 years. Treatment steps (1-5) were based on the Global Initiative for Asthma (GINA) guideline. Primary outcomes included time to treatment step switch (step-up or step-down) and time to first oral prednisolone/prednisone, and were compared between cohorts using Cox regression models.</p><p><strong>Results: </strong>In 2014, 2017 and 2020, 1193, 960 and 730 patients initiated asthma inhalers, respectively. In all cohorts, more than half of the patients initiated treatment at the lowest step. During 2-year follow-up, fewer patients switched their treatment steps in 2020 when compared with 2014 (adjusted hazard ratio (aHR): 0.86 (95% confidence interval (CI): 0.76-0.99). From 2014 to 2020, the likelihood of treatment stepping-down decreased over time, with a 21% in 2017 (aHR: 0.79 (0.68-0.92)) and 24% in 2020 (aHR: 0.76 (0.64-0.90)) compared to 2014, while the likelihood of stepping-up did not change significantly. The risk of taking oral prednisolone/prednisone was also significantly lower in 2020 (aHR: 0.76 (0.61-0.94)).</p><p><strong>Conclusion: </strong>During the pandemic, fewer asthma patients switched treatment steps and took oral prednisolone/prednisone. Since 2014, fewer individuals stepping down medication, with a decrease of 21% in 2017 and 24% in 2020. Possible drivers include improved adherence, better asthma control, and increased telemedicine use-trends that predate and have been accelerated by the pandemic. Research incorporating clinical data is necessary to confirm these hypotheses.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":"17 ","pages":"337-352"},"PeriodicalIF":3.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of Medication Proxies for the Identification of Hospitalizations for Major Adverse Cerebro-Cardiovascular Events.","authors":"Dennis Steenhuis, Xuechun Li, Talitha L Feenstra, Eelko Hak","doi":"10.2147/CLEP.S508754","DOIUrl":"10.2147/CLEP.S508754","url":null,"abstract":"<p><strong>Purpose: </strong>To date, complete and long-term registrations of diseases and events are not available in every situation. As a useful proxy, medication usage data is very promising. For instance, real-world dispensing data from pharmacies are attractive because of the high validity of drug dispensing data, large sample sizes, and long-term registration. However, before application as a proxy, validity must be assessed. Therefore, in this study, we aim to assess the validity of various medicines used as a proxy for major adverse cardio-cerebrovascular events (MACCE), that is, to identify an incident or previous hospitalization for a MACCE.</p><p><strong>Patients and methods: </strong>Using the claims database of a large Dutch healthcare insurer, we estimated the concordance between hospitalization claims for MACCE and specific claims for dispensings to treat MACCE in a cohort of patients on primary preventive antihypertensive and/or antihyperlipidemic therapy between 2013 and 2020.</p><p><strong>Results: </strong>In a cohort of more than 110,000 patients, a dispensing of either vitamin K antagonists, platelet aggregation inhibitors, or nitrates was predictive of an incident hospitalization for a MACCE between 2013 and 2020, with a sensitivity of 71.5% (95% CI: 70.4-72.5%) and specificity of 93.2% (95% CI 91.1-93.4%), and any history of hospitalization for a MACCE (prevalence) with a sensitivity of 86.9% (95% CI: 86.5-87.3%) and specificity of 81.9 (956% CI: 81.6-82.1%), while positive predicted value remains low. Sensitivity analyses across age, sex, and patients with asthma/COPD or diabetes showed a similarly good performance.</p><p><strong>Conclusion: </strong>Claims for the dispensings of vitamin K antagonists, platelet aggregation inhibitors, and/or nitrates can be validly used as a proxy for new and previous hospitalization for MACCE in patients on primary preventive therapy. Further study is required to assess the validity of such dispensing claims for non-hospitalized cerebro-cardiovascular events and whether the results are generalizable in non-Dutch cohorts.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":"17 ","pages":"327-336"},"PeriodicalIF":3.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Depression and Anxiety in Those Who Gave Birth to Children Who Developed Invasive <i>Group B Streptococcal</i> Disease: A Population-Based Cohort Study.","authors":"Erzsébet Horváth-Puhó, Jaya Chandna, Proma Paul, Claire A Wilson, Henrik T Sørensen, Joy E Lawn","doi":"10.2147/CLEP.S506809","DOIUrl":"10.2147/CLEP.S506809","url":null,"abstract":"<p><strong>Background: </strong>Mental disorders such as depression and anxiety are common for women of reproductive age and impact pregnancy and parenting. Invasive <i>Group B Streptococcus</i> disease (iGBS) is a leading cause of neonatal morbidity and mortality worldwide. Little is known about the short and long-term risk of common mental disorders in birthing parents whose infants had iGBS in the first 89 days after birth. We aimed to examine the risk of depression and anxiety in birthing parents with iGBS-affected infants in a cohort study with prospectively collected data from Danish registries.</p><p><strong>Materials and methods: </strong>Using Danish healthcare registries from 1997 to 2018, we obtained data on iGBS-affected children and their birthing parents. A comparison cohort was randomly sampled (1:50) through risk-set sampling, and matched on persons' age, year of child´s birth, and parity. The risk of using antidepressant medicines and depression or anxiety diagnosis was analyzed with cumulative incidence function and in Cox proportional hazards regression models.</p><p><strong>Results: </strong>During the study period, we identified 1,552 women with iGBS-affected child and 76,879 matched comparators. During a median follow-up of 9∙9 years, the cumulative incidence of antidepressants use among birthing parents with iGBS-affected children was 31% (95% confidence interval, CI: 28-34%), as compared with 29% (95% CI: 28-30%) among members of the comparison cohort (hazard ratio 1∙12 [95% CI: 1∙01-1∙25]). A 16% increase in the rate of diagnosed depression or anxiety was observed in the overall follow-up period.</p><p><strong>Conclusion: </strong>Our findings provide evidence of a slightly increased risk of antidepressant use and diagnosed depression or anxiety in parents who gave birth to children with a history of iGBS compared to a matched cohort of birthing parents whose infants did not develop iGBS. Our findings highlight the importance of addressing the mental health needs of birthing parents affected by their children' iGBS.</p>","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":"17 ","pages":"315-325"},"PeriodicalIF":3.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}